{
  "id": 15501955,
  "title": "Veradermics to present phase 3 hair loss trial results Monday",
  "url": "https://urgent.news/2026/10/18/veradermics-to-present-phase-3-hair-loss-trial-results-monday",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-18T22:04:39.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/company-news/veradermics-to-present-phase-3-hair-loss-trial-results-monday-93CH-4956109"
  },
  "original_language": "en",
  "account": "New Haven, Conn. - Veradermics, Inc. (NYSE: MANE) is set to hold an investor call on Monday at 8:00 a.m. ET to discuss the results from Part A of its Phase 3 clinical trial assessing the efficacy of VDPHL01 in treating pattern hair loss, according to a press release. The randomized, double-blind, placebo-controlled study, known as Study 304, included more than 500 male participants with mild-to-moderate pattern hair loss. The trial evaluated an extended-release oral minoxidil formulation, specifically VDPHL01, at two different dosages. VDPHL01 is an investigational drug currently in Phase 3 development for both male and female pattern hair loss. The company's registration-directed clinical development program includes three multicenter trials involving over 1,600 adult males and females with mild-to-moderate pattern hair loss. Each trial lasts 52 weeks, with a six-month placebo-controlled period followed by an additional six-month extension. The trials aim to support potential FDA approval of VDPHL01, which, if approved, would be the first FDA-approved oral non-hormonal treatment for pattern hair loss in both male and female populations. The investor call will be available on the company's website, with a replay provided afterward.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}